This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ cloperastine hydrochloride,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Cough Suppression: Cloperastine hydrochloride is used to alleviate cough symptoms associated with respiratory conditions such as the common cold, influenza, bronchitis, sinusitis, and allergies. It works by suppressing the cough reflex in the central nervous system, thereby reducing the frequency and intensity of coughing episodes. Cloperastine hydrochloride is particularly effective in managing non-productive or dry coughs, where there is no significant mucus production.

  2. Antitussive Activity: Cloperastine hydrochloride acts centrally in the brain to inhibit the cough reflex, rather than directly affecting the respiratory tract. It exerts its antitussive effects by binding to sigma-1 receptors and blocking the transmission of cough signals along the cough reflex pathway. This mechanism of action distinguishes cloperastine hydrochloride from other cough suppressants, such as opioids or expectorants, which may have different modes of action or side effect profiles.

  3. Efficacy: Cloperastine hydrochloride has been shown to be effective in reducing cough frequency and severity in clinical studies and trials involving patients with various respiratory conditions. It is often used as a symptomatic treatment to provide relief from bothersome cough symptoms while underlying respiratory infections or conditions resolve. Cloperastine hydrochloride may be used alone or in combination with other medications, depending on the nature and severity of the cough.

  4. Safety and Tolerability: Cloperastine hydrochloride is generally well-tolerated by most individuals when used at recommended doses. Common side effects may include drowsiness, dizziness, headache, gastrointestinal upset (such as nausea or vomiting), dry mouth, and allergic reactions (such as skin rash or itching). These side effects are usually mild and transient, resolving with continued use or upon discontinuation of the medication. Serious adverse reactions to cloperastine hydrochloride are rare but may include hypersensitivity reactions or respiratory depression in susceptible individuals.

  5. Dosage and Administration: Cloperastine hydrochloride is available in various oral formulations, including tablets, capsules, syrups, and lozenges, for administration according to the age and weight of the patient. The dosage and frequency of cloperastine hydrochloride therapy depend on factors such as the severity of cough symptoms, the patient's age and medical condition, and the specific formulation used. Patients should follow the instructions provided by their healthcare provider or medication label for proper dosing and administration.

  6. Contraindications and Precautions: Cloperastine hydrochloride is contraindicated in individuals with known hypersensitivity to cloperastine or any of its components. It should be used with caution in patients with impaired renal or hepatic function, respiratory disorders (such as asthma or chronic obstructive pulmonary disease), or a history of substance abuse or addiction. Cloperastine hydrochloride may interact with other medications, particularly central nervous system depressants or monoamine oxidase inhibitors (MAOIs), increasing the risk of adverse effects or drug interactions.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of cloperastine hydrochloride,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bacteroides uniformis Reduces
species Faecalibacterium prausnitzii Reduces
species Parabacteroides distasonis Reduces

Bacteria Impacted by cloperastine hydrochloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

πŸ““ Direct Citations πŸ‘ͺπŸ‘Ά Indirect Citations Taxonomy Rank Effect
0 1 Akkermansiaceae family Decreases
0 1 Phocaeicola genus Decreases
0 1 Lachnospira genus Decreases
0 1 Bilophila genus Decreases
0 1 Bacteroides genus Decreases
0 1 Segatella genus Decreases
0 1 Agathobacter genus Decreases
1 0 Akkermansia genus Decreases
0 1 Enterocloster genus Decreases
0 1 Parabacteroides genus Decreases
0 1 Roseburia genus Decreases
0 1 Thomasclavelia genus Decreases
0 1 Lacrimispora genus Decreases
0 1 Streptococcus genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Collinsella genus Decreases
0 1 Blautia genus Decreases
0 1 Dorea genus Decreases
0 1 Coprococcus genus Decreases
0 1 environmental samples no rank Decreases
0 1 unclassified Akkermansia no rank Decreases
1 0 Bilophila wadsworthia species Decreases
1 0 Segatella copri species Decreases
1 0 Agathobacter rectalis species Decreases
1 0 Bacteroides fragilis species Decreases
1 0 Bacteroides uniformis species Decreases
1 0 Lachnospira eligens species Decreases
1 0 Parabacteroides distasonis species Decreases
1 0 Phocaeicola vulgatus species Decreases
1 0 Akkermansia muciniphila species Decreases
1 0 Enterocloster bolteae species Decreases
1 0 Roseburia intestinalis species Decreases
1 0 Bacteroides thetaiotaomicron species Decreases
1 0 Thomasclavelia ramosa species Decreases
1 0 Bacteroides xylanisolvens species Decreases
1 0 Lacrimispora saccharolytica species Decreases
0 1 Segatella bryantii species Decreases
1 0 Streptococcus salivarius species Decreases
0 1 Bacteroides sp. CACC 737 species Decreases
0 1 Streptococcus sp. FDAARGOS_192 species Decreases
0 1 Leyella stercorea species Decreases
1 0 Mediterraneibacter gnavus species Decreases
1 0 Parabacteroides merdae species Decreases
0 1 Bacteroides sp. A1C1 species Decreases
1 0 Collinsella aerofaciens species Decreases
0 1 Bacteroides humanifaecis species Decreases
0 1 Bacteroides sp. HF-162 species Decreases
0 1 Alistipes sp. dk3624 species Decreases
0 1 Flavonifractor plautii species Decreases
0 1 Hungatella hathewayi species Decreases
0 1 Bacteroides luhongzhouii species Decreases
0 1 Prevotella intermedia species Decreases
0 1 Leyella lascolaii species Decreases
0 1 Paraprevotella clara species Decreases
0 1 Prevotella bivia species Decreases
0 1 Bacteroides faecium species Decreases
0 1 Bacteroides sp. DH3716P species Decreases
0 1 Roseburia rectibacter species Decreases
0 1 Enterocloster clostridioformis species Decreases
0 1 Prevotella dentalis species Decreases
0 1 Blautia parvula species Decreases
0 1 Faecalibacterium prausnitzii species Decreases
0 1 Akkermansia glycaniphila species Decreases
0 1 Akkermansia massiliensis species Decreases
0 1 Candidatus Akkermansia intestinavium species Decreases
1 0 Blautia obeum species Decreases
1 0 Dorea formicigenerans species Decreases
1 0 Coprococcus comes species Decreases

Impact of cloperastine hydrochloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.8 0.8
ADHD 1.5 0 0
Age-Related Macular Degeneration and Glaucoma 0.3 0.2 0.5
Allergic Rhinitis (Hay Fever) 0.9 0.4 1.25
Allergies 1.4 1.9 -0.36
Allergy to milk products 1 0.6 0.67
Alopecia (Hair Loss) 0.7 0.7
Alzheimer's disease 3.2 3.9 -0.22
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.1 0.6 2.5
Ankylosing spondylitis 2.7 1 1.7
Anorexia Nervosa 0.4 2.2 -4.5
Antiphospholipid syndrome (APS) 1 0.3 2.33
Asthma 2.2 1.6 0.38
Atherosclerosis 1.2 1 0.2
Atrial fibrillation 2.2 2.1 0.05
Autism 4.5 6.3 -0.4
Autoimmune Disease 0.1 0.2 -1
Barrett esophagus cancer 0.1 -0.1
benign prostatic hyperplasia 0.3 -0.3
Biofilm 0.3 0.3
Bipolar Disorder 1 0.3 2.33
Brain Trauma 0.2 0.7 -2.5
Carcinoma 1.1 0.7 0.57
Celiac Disease 2.1 1.7 0.24
Cerebral Palsy 0.7 0.6 0.17
Chronic Fatigue Syndrome 1.9 3.3 -0.74
Chronic Kidney Disease 0.9 2.1 -1.33
Chronic Lyme 0.6 -0.6
Chronic Obstructive Pulmonary Disease (COPD) 0.4 0.8 -1
Chronic Urticaria (Hives) 0.1 1.9 -18
Coagulation / Micro clot triggering bacteria 0.4 0.4 0
Cognitive Function 0.8 0.4 1
Colorectal Cancer 3.7 1.4 1.64
Constipation 1.4 0.3 3.67
Coronary artery disease 0.7 1.9 -1.71
COVID-19 4 7 -0.75
Crohn's Disease 4.5 4.1 0.1
Cushing's Syndrome (hypercortisolism) 0.9 -0.9
cystic fibrosis 0.6 -0.6
deep vein thrombosis 0.9 0.7 0.29
Denture Wearers Oral Shifts 0.3 0.3
Depression 5.5 4.4 0.25
Dermatomyositis 0.1 0.1
Eczema 0.4 0.9 -1.25
Endometriosis 0.9 0.7 0.29
Eosinophilic Esophagitis 0.1 -0.1
Epilepsy 1.5 1.6 -0.07
erectile dysfunction 0.3 0.3
Fibromyalgia 1.4 1.6 -0.14
Functional constipation / chronic idiopathic constipation 2.8 2.3 0.22
gallstone disease (gsd) 1.1 0.5 1.2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.3 0.6 1.17
Generalized anxiety disorder 0.9 0.7 0.29
Glioblastoma 0.1 -0.1
Gout 1.1 0.3 2.67
Graves' disease 0.6 0.9 -0.5
Gulf War Syndrome 0.1 1.9 -18
Halitosis 0.4 0.1 3
Hashimoto's thyroiditis 1.5 1.5 0
Heart Failure 1.5 1.3 0.15
hemorrhagic stroke 0.3 0.3
Hidradenitis Suppurativa 1.2 1.2
High Histamine/low DAO 0.2 0.2
hypercholesterolemia (High Cholesterol) 0.6 -0.6
hyperglycemia 0.4 1.5 -2.75
Hyperlipidemia (High Blood Fats) 0.7 0.1 6
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 2.3 3 -0.3
Hypothyroidism 0.4 0 0
Hypoxia 0.8 0.8
IgA nephropathy (IgAN) 0.7 2.9 -3.14
Inflammatory Bowel Disease 3.1 6.2 -1
Insomnia 0.7 2.3 -2.29
Intelligence 0.9 0.7 0.29
Intracranial aneurysms 0.7 0.2 2.5
Irritable Bowel Syndrome 2.7 3.7 -0.37
ischemic stroke 0.7 1 -0.43
Liver Cirrhosis 2.7 2 0.35
Long COVID 4.3 3.7 0.16
Low bone mineral density 0.7 -0.7
Lung Cancer 0.3 0.7 -1.33
Mast Cell Issues / mastitis 0.1 0 0
ME/CFS with IBS 0.6 0.5 0.2
ME/CFS without IBS 0.3 0.9 -2
membranous nephropathy 0.1 0.1
Menopause 0.1 0.5 -4
Metabolic Syndrome 3.3 4 -0.21
Mood Disorders 5.4 3.6 0.5
multiple chemical sensitivity [MCS] 0.6 0.1 5
Multiple Sclerosis 2.7 4.1 -0.52
Multiple system atrophy (MSA) 0.8 0 0
myasthenia gravis 0.1 0.2 -1
neuropathic pain 1.7 -1.7
Neuropathy (all types) 0.4 0.6 -0.5
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.3 2.7 -0.17
NonCeliac Gluten Sensitivity 1 0.3 2.33
Obesity 4.1 3.7 0.11
obsessive-compulsive disorder 3 2.1 0.43
Osteoarthritis 1.7 0.8 1.13
Osteoporosis 0.6 1 -0.67
pancreatic cancer 0.1 0.1 0
Parkinson's Disease 3.6 4.7 -0.31
Polycystic ovary syndrome 3.3 1.3 1.54
Postural orthostatic tachycardia syndrome 0 0
Premenstrual dysphoric disorder 0.1 0.2 -1
primary biliary cholangitis 0.1 0.8 -7
Primary sclerosing cholangitis 0.7 1.2 -0.71
Psoriasis 1.2 3.2 -1.67
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 3.1 2 0.55
Rosacea 0.1 0.3 -2
Schizophrenia 2.8 1.6 0.75
scoliosis 0 0.9 0
Sjögren syndrome 1.1 1.6 -0.45
Sleep Apnea 0 0.6 0
Slow gastric motility / Gastroparesis 0.3 0.3
Small Intestinal Bacterial Overgrowth (SIBO) 0.4 0.4
Stress / posttraumatic stress disorder 1.1 1.6 -0.45
Systemic Lupus Erythematosus 1.8 1.1 0.64
Tic Disorder 0.7 0.9 -0.29
Tourette syndrome 0.4 0.3 0.33
Type 1 Diabetes 2.6 1.9 0.37
Type 2 Diabetes 4.5 4.1 0.1
Ulcerative colitis 2.9 4.9 -0.69
Unhealthy Ageing 2.8 1.4 1
Vitiligo 1.8 0.5 2.6

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]